Journal article
Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma
British journal of haematology, Vol.174(4), pp.536-540
08/2016
DOI: 10.1111/bjh.14081
PMID: 27172326
Abstract
Response to treatment in patients with a plasma cell disorder is typically measured by evaluating the bone marrow and myeloma markers, including monoclonal protein spike and immunofixation (IFE) in blood and urine, and serum free light chains (sFLCs). Stringent complete response criteria for Multiple Myeloma (MM) patients require a normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. We performed a retrospective chart review to further evaluate these criteria. A total of 142 patient charts were analysed. Of these, 17 patients were found to have an abnormal sFLC ratio, but no other evidence of disease, including normal flow cytometry and normal fluorescence in situ hybridization (FISH) analysis on highly selected plasma cells. In all patients, the abnormal sFLC ratio was caused by abnormalities in the serum kappa light chains. These results suggest that current definitions may need to be revised to take aberrancies related to abnormal immune recovery into account.
Details
- Title: Subtitle
- Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma
- Creators
- Kamal Kant Singh Abbi - Division of Hematology/Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USAMargarida Silverman - Division of Hematology/Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USAUmar Farooq - Division of Hematology/Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USAAnnick Tricot - Division of Hematology/Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USALindsey Dozeman - Division of Hematology/Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USAKalyan Nadiminti - Division of Hematology/Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USAMatthew D Krasowski - Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USAGuido J Tricot - Division of Hematology/Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
- Resource Type
- Journal article
- Publication Details
- British journal of haematology, Vol.174(4), pp.536-540
- Publisher
- England
- DOI
- 10.1111/bjh.14081
- PMID
- 27172326
- ISSN
- 0007-1048
- eISSN
- 1365-2141
- Grant note
- P30 CA086862 / NCI NIH HHS
- Language
- English
- Date published
- 08/2016
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Internal Medicine
- Record Identifier
- 9984047670602771
Metrics
13 Record Views